Diabetes-associated sustained activation of the transcription factor nuclear factor-κB

Diabetes

Volumn 50, Issue 12, 2001, Pages 2792-2808

  Bierhaus, Angelika ^a,b   Schiekofer, Stephan ^a,b   Schwaninger, Markus ^a,h   Andrassy, Martin ^a,b   Humpert, Per M ^b   Chen, Jiang ^a,b   Hong, Mei ^b   Luther, Thomas ^c   Henle, Thomas ^c   Klöting, Ingrid ^d   Morcos, Michael ^a   Hofmann, Marion ^e   Tritschler, Hans ^f   Weigle, Bernd ^c   Kasper, Michael ^c   Smith, Mark ^g   Perry, George ^g,h   Schmidt, Ann Marie ^e   Stern, David M ^e   Häring, Hans Ulrich ^b   Schleicher, Erwin ^b   Nawroth, Peter P ^a,b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Department of Physiology ^*  (United States)

^f ASTA MEDICA AG   (Germany)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Prion Development Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCTS BOVINE SERUM ALBUMIN; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; BOVINE SERUM ALBUMIN; DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; MESSENGER RNA; NF KAPPA B P65; NF-KAPPA B P65; PROTEIN S 100;

ADULT; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL NUCLEUS; CYTOPLASM; FEEDBACK SYSTEM; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MONOCYTE; MOUSE; PHYSIOLOGY; RAT; RAT STRAIN; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ADULT; AMYLOID BETA-PROTEIN; ANIMAL; CELL NUCLEUS; CYTOPLASM; DIABETES MELLITUS, INSULIN-DEPENDENT; DNA; ENDOTHELIUM, VASCULAR; FEEDBACK; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN; I-KAPPA B; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; S100 PROTEINS; SERUM ALBUMIN, BOVINE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035656173     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.12.2792     Document Type: Article

References (115)

1. Barnes PJ, Karin M: Nuclear Factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997
2. May MJ, Ghosh S: Rel/NF-kappa B, and I kappa B proteins: an overview. Semin Cancer Biol 8:63-73, 1997
3. Baeuerle PA, Baltimore D: NF-κB: ten years after. Cell 87:13-20, 1996
4. Verma I, Stevenson JK, Schwarz EM, van Antwerp D, Miyamoto S: Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev 9:2723-2735, 1995
5. Baeuerle PA, Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141-179, 1994
6. Collins T: Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 68:499-508, 1993
7. Read MA, Whitley MZ, Williams AJ, Collins T: NF-kappa B, and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 179:503-512, 1994
8. Mercurio F, Manning AM: NF-κB as a primary regulator of the stress response. Oncogene 18:6163-6171, 1999
9. Beg AA, Baldwin AS: The IκBproteins: multifunctional regulators of Rel/NF-κB transcription factors. Genes Dev 7:2064-2070, 1993
10. Alkalay I, Yaron A, Hatzubai A, Orian A, Chiechanover A, Ben-Neriah Y: Stimulation-dependent IκBα: phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 92:10599-10603, 1995
11. de-Martin R, Vanhove B, Cheng Q, Hofer E, Csizmadia V, Winkler H, Bach FH: Cytokine-inducible expression in endothelial cells of an I kappa B alpha-like gene is regulated by NF kappa B. EMBO J 12:2773-2779, 1993
12. Ruef J, Peter K, Nordt TK, Runge MS, Kübler W, Bode C: Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 82 (Suppl. 1):32-37, 1999
13. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle P, Neumeier D: Activated transcription factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97:1715-1722, 1996
14. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
15. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
16. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-789, 2000
17. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P: Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105:439-461, 1998
18. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier J, Stern D: Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat Med 1:693-699, 1995
19. Nunomura A, Perry G, Pappola MA, Wade R, Hirai K, Chiba S, Smith MA: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19:1959-1964, 1999
20. Beg AA, Baltimore D: An essential role of NF-κB in preventing TNFα-induced cell death. Science 274:782-784, 1996
21. Badrichani AZ, Stroka DM, Bilbao G, Curiel DT, Bach FH, Ferran C: Bcl-2 and Bcl-XI serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB. J Clin Invest 103:543-553, 1999
22. Van Antwerp D, Martin S, Jafri T, Green D, Verma I: Suppression of TNFα-induced apoptosis by NF-κB. Science 274:787-789, 1996
23. Bach FH, Hancock WW, Ferran C: Protective genes expressed in endothelial cell: a regulatory response to injury. Immunol Today 18:483-486, 1997
24. Schmidt AM, Yan SD, Stern DM: The dark side of glucose. Nat Med 1:1002-1004, 1995
25. Vlassara H, Bucala R, Striker L: Pathogenetic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
26. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP: The AGE/RAGE pathway in vascular disease and diabetes mellitus. Part I. The AGE-concept. Cardiovasc Res 37:586-600, 1998
27. Hofmann MA, Drury S, Fu C, Wu Q, Taguchi A, Lu Y, Avila C, Kambham N, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Bierhaus A, Neurath M, Nawroth P, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: the cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901, 1999
28. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Rohrer A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643-651, 2000
29. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagahima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691, 1996
30. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G: Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 91:5710-5714, 1994
31. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern DM, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996
32. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern DM: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 96:1395-1403, 1995
33. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E: Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 92:747-750, 1996
34. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A: Immunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 15:571-582, 1995
35. Miyata T, Inagi R, Ilida Y, Sato N, Yamada N, Oda O, Maeda K, Seo H: Involvement of beta-2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis associated amyloidosis. J Clin Invest 93:521-528, 1994
36. Schleicher ED, Wagner E, Nerlich AG: Increased accumulation of the glycoxidation product Ne-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468, 1997
37. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW: The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-13, 1999
38. Suzuki D, Miyata T: Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38:309-314, 1999
39. Sebokova K, Blazicek P, Syrova D, Krvosikowa Z, Spustova V, Heidland A, Schinzel R: Circulating advanced glycation end products levels in rats rapidly increase with acute renal failure. Kidney Int Suppl 78:S58-S62, 2001
40. Berg TJ, Clausen JT, Torjesen AA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF: The advanced glycation endproduct Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21:1997-2002, 1998
41. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
42. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern DM: Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14:1521-1528, 1994
43. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497, 1999
44. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
45. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
46. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Wahl P, Stern DM, Nawroth PP: Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146:688-694, 1995
47. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E, Waldherr R, Stern DM, Nawroth PP: Expression of receptors for advanced glycosylated end products in renal disease. Nephrol Dial Transplant 10:1662-1667, 1995
48. Greten J, Zhang Y, Wiesel R, Ritz E, Ziegler R, Wahl P, Nawroth PP: Expression of receptors for advanced glycation end products in uremia. Nephrol Dial Transplant 11:786-790, 1996
49. Taguchi A, Blood GC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastasis. Nature 405:354-360, 2000
50. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli AD, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712, 1993
51. Bierhaus A, Chevion S, Chevion M, Quehenberger P, Hofmann M, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Ziegler R, Nawroth PP: Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 46:1481-1490, 1997
52. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP: Advanced glycation endproducts (AGEs) mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262-2271, 1997
53. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, Guillausseau P-J, Stern DM: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91:7742-7746, 1994
54. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dorken B: Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94:3129-3134, 1999
55. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N: Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93:2360-2368, 1999
56. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952-2960, 1997
57. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J: Genistein inhibits constitutive and inducible NFκB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 155:473-481, 1999
58. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C: Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18:943-953, 1999
59. Bourcier T, Sukhova G, Libby, P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272:15817-215824, 1997
60. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 2:998-1004, 1996
61. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, Ziegler R, Nawroth PP: Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease. Gut 45:693-704, 1999
62. Yang F, de Villiers WJ, Lee EY, McClain CJ, Varilek GW: Increased nuclear factor-kappaB activation in colitis of interleukin-2-deficient mice. J Lab Clin Med 134:378-385, 1999
63. Hauf N, Goebel W, Fiedler F, Sokolovic Z, Kuhn M: Listeria monocytogenes infection of P388D1 macrophages results in a biphasic NF-κB (RelA/p50) activation induced by lipoteichoic acid and bacterial phospholipases and mediated by IκBα and IκBβ degradation. Proc Natl Acad Sci U S A 94:9394-9399, 1997
64. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S: IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 80:573-582, 1995
65. Johnson DR, Douglas I, Jahnke A, Ghosh S, Pober JS: A sustained reduction in IκB-β may contribute to persistent NF-κB activation in human endothelial cells. J Biol Chem 271:16317-16322, 1996
66. Cheshire JL, Baldwin AS Jr: Synergistic activation of NF-κB by tumor necrosis factor alpha and gamma interferon via enhanced IκBα degradation and de novo IκBβ degradation. Mol Cell Biol 17:6746-6754, 1997
67. Suyang H, Phillips R, Douglas I, Ghosh S: Role of unphosphorylated, newly synthesized IκBβ in persistent activation of NF-κB. Mol Cell Biol 16:5444-5449, 1996
68. Costello R, Lipcey C, Algarte M, Cerdan C, Baeuerle P, Olive D, Imbert J: Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kB. Cell Growth Differ 4:329-339, 1993
69. Kahn-Perles B, Lipcey C, Lécine P, Olive D, Imbert J: Temporal and subunit-specific modulations of the Rel/NF-kB transcription factors through CD28 costimulation. J Biol Chem 272:21774-21783, 1997
70. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP: Endothelin-1 transcription is under control of nuclear factor-κB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561-1570, 2000
71. Henle T, Walter H, Krause I, Klostermeyer H: Efficient determination of individual Maillard compounds in heat-treated milk products by amino acid analysis. Int Dairy J 1:125-135, 1991
72. Henle T, Schwarzenbolz U, Klostermeyer H: Detection and quantification of pentosidine in foods. Z Lebensm Unters Forsch 204:95-98, 1997
73. Finot PA, Deutsch R, Bujard E: The extent of the Maillard reaction during the processing of milk. Prog Food Nutr Sci 5:345-355, 1981
74. Schleicher E, Wieland OH: Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other glycosylated proteins. J Clin Chem Clin Biochem 19:81-87, 1981
75. Henle T, Walter AW, Klostermeyer H: Simultaneous determination of protein-bound Maillard products by ion-exchange chromatography and photodiode array detection. In Maillard Reactions in Chemistry, Food, and Health. Labuza TP, Reineccius GA, Monnier VM, O'Brien J, Baynes JW, Eds. London, The Royal Society of Chemistry, 1994, p. 195-200
76. Henle T, Schwarzenbolz U, Walter AW, Klostermeyer H: Protein-bound Maillard compounds in foods: analytical and technological aspects. In The Maillard Reaction in Foods and Medicine. O'Brien J, Nursten HE, Crabbe MJC, Ames JM, Eds. London, The Royal Society of Chemistry, 1998, p. 178-183
77. Henle T, Bachmann A: Synthesis of pyrraline. Z Lebensm Unters Forsch 202:72-75, 1996
78. Lernbecher T, Muller U, Wirth T: Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 365:767-770, 1993
79. Klöting I, Vogt L: BB/O(ttawa)K(arlsburg) rats: features of a subline of diabetes-prone BB rats. Diabetes Res 18:79-87, 1991
80. Hofmann M, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP: Insufficient glycemic control increases NF-κB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21:1310-1316, 1998
81. Hofmann M, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP: Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrate increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222-232, 1999
82. Böhrer H, Qiu F, Zimmermann T, Zhang Y, Illmer T, Männel D, Böttiger BW, Stern DM, Waldherr R, Saeger H-D, Ziegler R, Bierhaus A, Martin E, Nawroth PP: Role of NF-κB in the mortality of sepsis. J Clin Invest 100:972-985, 1997
83. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Müller M, Böhrer H, Greten J, Martin E, Baeuerle PA, Waldherr R, Kisiel W, Ziegler R, Stern DM, Nawroth PP: Mechanism of the TNFα mediated induction of endothelial tissue factor. J Biol Chem 270:26419-26432, 1995
84. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Müller M, Mackman N, Ziegler R, Nawroth PP: The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 77:772-782, 1997
85. Rodriguez MS, Michalopopulus I, Aenzana-Seisdedos F, Hay RT: Inducible degradation of IκBα in vitro and in vivo requires the acidic c-terminal domain of the protein. Mol Cell Biol 15:2413-2419, 1995
86. Peng HP, Libby P, Liao JK: Induction and stabilisation of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 270:14214-14219, 1995
87. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740-745, 1986
88. Lin J, Liliensiek B, Kanitz M, Schimanski U, Böhrer H, Waldherr R, Martin E, Kauffmann G, Ziegler R, Nawroth PP: Molecular cloning of genes differentially regulated by TNF-alpha in bovine aortic endothelial cells, fibroblasts and smooth muscle cells. Cardiovasc Res 38:802-813, 1998
89. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest 101:1905-1915, 1998
90. Dosquet C, Weill D, Wautier JL: Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol 34 (Suppl.): S55-S59, 1992
91. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436-9440, 1994
92. Vlassara H, Striker LJ, Teichberg H, Fuh YM, Li M, Steffes M: Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
93. Pahl HL, Baeuerle PA: The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 2:63-67, 1997
94. Berg TJ, Dahl-Jorgensen K, Torjesen PA, Hanssen KF: Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 20:1006-1008, 1997
95. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R: Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 347:513-515, 1996
96. Makita Z, Radoff S, Rayfield E, Yang Z, Skolnik E, Friedmann EA, Cerami A, Vlassara H: Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 325:830-882, 1991
97. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474-6479, 1997
98. Li Y-M, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A 93:3902-3907, 1996
99. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H: Advanced glycation end products (AGEs) colocalize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 150:523-539, 1997
100. Willis D, Moore AR, Frederick R, Willoughby DA: Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 2:87-90, 1996
101. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170:1387-1407, 1989
102. Lindner V, Collins T: Expression of NF-κB and IκB-α by aortic endothelium in an arterial injury model. Am J Pathol 148:427-438, 1996
103. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle P, Schölmerich J, Gross V: Nuclear factor κB is activated in macrophages and epithelial cells of inflamed mucosa. Gastroenterology 115:357-369, 1998
104. Yin K, Juurlink BH: Regulation of expression of nuclear factor kappa B rel A in oligodendrocytes: effects of hypoxia. Neuroreport 11:1877-1881, 2000
105. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by RAGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694, 2001
106. 2 terminal kinase-mediated redox-dependent degradation of IκB: role of thioredoxin in NF-κB activation. J Biol Chem 276:4662-4670, 2001
107. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94:3633-3638, 1997
108. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T: Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19:6367-6378, 1999
109. Lander H, Tauras J, Ogiste J, Moss R, Schmidt AM: Activation of RAGE triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814, 1997
110. Nishibe T, Parry G, Ishida A, Aziz M, Murray J, Patel Y, Rahman S, Strand K, Saito K, Saito Y, Hammond WP, Savidge GF, Mackman N, Wijelath ES: Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk1/2 activation. Blood 97:692-699, 2001
111. Abu-Am Y, Ross FP, McHugh KP, Livolsi A, Peyron JF, Teitelbaum SL: Tumor necrosis factor-α activation of nuclear transcription factor κB in marrow macrophages is mediated by c-SRC tyrosine phosphorylation of IκBα. J Biol Chem 273:29417-29423, 1998
112. Yurochko AD, Mayo ME, Poma EE, Baldwin AS, Huang ES: Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol 71:4638-4648, 1997
113. Li J, Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272:16498-16506, 1997
114. Perry G, Nunomura A, Lucassen P, Lassmann H, Smith MA: Apoptosis and Alzheimer's disease (Letter). Science 282:1268-1269, 1999
115. Smith MA, Joseph JA, Perry G. Arson: Tracking the culprit in Alzheimer's disease. Ann N Y Acad Sci 924:35-38, 2000